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The firing pattern of midbrain dopamine (DA) neurons is well known to reflect reward prediction errors (PEs), the difference between
obtained and expected rewards. The PE is thought to be a crucial signal for instrumental learning, and interferencewithDA transmission
impairs learning. Phasic increases of DA neuron firing during positive PEs are driven by activation of NMDA receptors, whereas phasic
suppression of firing during negative PEs is likelymediated by inputs from the lateral habenula.We aimed to determine the contribution
of DA D2-class and NMDA receptors to appetitively and aversively motivated reinforcement learning. Healthy human volunteers were
scanned with functional magnetic resonance imaging while they performed an instrumental learning task under the influence of either
theDAD2receptor antagonist amisulpride (400mg), theNMDAreceptor antagonistmemantine (20mg), orplacebo.Participantsquickly
learned to select (“approach”) rewarding and to reject (“avoid”) punishing options. Amisulpride impaired both approach and avoidance
learning, while memantinemildly attenuated approach learning but had no effect on avoidance learning. These behavioral effects of the
antagonists were paralleled by theirmodulation of striatal PEs. Amisulpride reduced both appetitive and aversive PEs, whilememantine
diminished appetitive, but not aversive PEs. These data suggest that striatal D2-class receptors contribute to both approach and avoid-
ance learning by detecting both the phasic DA increases and decreases during appetitive and aversive PEs. NMDA receptors on the
contrary appear to be required only for approach learning because phasic DA increases during positive PEs are NMDA dependent,
whereas phasic decreases during negative PEs are not.
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Introduction
Learning to select those stimuli or actions that result in rewards
and to avoid those that result in punishments is crucial for adap-
tive success. Formal learning theory posits that learning is driven
by prediction errors (PEs), the difference between experienced
and expected outcome (Rescorla and Wagner, 1972; Sutton and
Barto, 1998). If an action leads to an outcome that is better than
expected, this results in a positive PE, and the action’s value is
increased. If the outcome is worse than expected, a negative PE
results and the value of the action is decreased. The firing pattern
of midbrain dopamine (DA) neurons in a number of species,
including humans, has been shown to reflect PE (Schultz et al.,
1997; Hollerman and Schultz, 1998; Satoh et al., 2003; Bayer and
Glimcher, 2005; Roesch et al., 2007; Takahashi et al., 2009;
Zaghloul et al., 2009). It is commonly assumed that this dopami-
nergic PE is then broadcast to target structures of the midbrain
DA system, in particular the basal ganglia. There, it is thought to
act as a teaching signal by modifying plasticity at corticostriatal
synapses (Schultz et al., 1997; Shen et al., 2008). Activity corre-
lated with PE has also been found in a vast number of human
neuroimaging studies, where it is usually observed in areas that
receive the densest DA projections, such as striatum and prefron-
tal cortex (O’Doherty et al., 2004; Pessiglione et al., 2006, 2008;
Jocham et al., 2009, 2011; Valentin and O’Doherty, 2009). More
recently, human functional magnetic resonance imaging (fMRI)
studies have also found that PE correlates directly in the DA
neuron containing midbrain substantia nigra and ventral teg-
mental area (D’Ardenne et al., 2008; Klein-Flu¨gge et al., 2011).
Striatal PE correlates with learning success (Scho¨nberg et al.,
2007), and precise temporal modulation of DA neuron firing
using optogenetics indicates a causal role for PEs in learning
(Steinberg et al., 2013). Evidence accrues that positive and nega-
tive PEs are generated by different mechanisms. NMDA gluta-
mate receptors located onmidbrain DA neurons appear essential
for the phasic bursts during positive PEs (Overton and Clark,
1992; Wang et al., 2011). In contrast, inputs from the lateral
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habenula, which is excited by aversive events (Ullsperger and von
Cramon, 2003; Matsumoto and Hikosaka, 2009; Bromberg-
Martin et al., 2010) seem to drive suppression of DA neuron
firing during negative PEs (Matsumoto and Hikosaka, 2007).
Our present study was aimed to determine the different roles of
NMDA and DA receptors in instrumental approach and avoid-
ance learning. We hypothesized that NMDA receptor antago-
nism would impair learning to approach appetitive stimuli by
interfering with the generation of positive PEs, while having no
effect on learning to avoid aversive stimuli. In contrast, we ex-
pected that blockade of DA D2 receptors would interfere with
both approach and avoidance learning, because those receptors
are sensitive to both increases and decreases in extracellular DA
levels associated with rewards and punishments, respectively.We
addressed this hypothesis by scanning healthy human volunteers
with fMRI while they performed an instrumental approach and
avoidance learning task under the influence of either placebo or
antagonists of D2-like and NMDA receptors.
Materials andMethods
Participants. Twenty-four healthy male participants [age, 25.46  0.53
years; body weight, 80.5  2.6 kg (mean  SEM)] participated in the
experiment. We excluded female subjects to avoid menstrual cycle-
dependent interactions between the dopaminergic system and gonadal
steroids (Becker et al., 1982; Becker and Cha, 1989; Creutz and Kritzer,
2004; Dreher et al., 2007). We excluded two participants because they
performed a substantial number of misses on 1 of the three sessions
(40 misses on 270 trials; see Results), which prevented reliable calcula-
tion of learning curves. All analyses reported here are from the final
sample of n  22 volunteers. All participants gave written informed
consent to the procedure, which had been approved by the local ethics
committee of theMedical Faculty of theUniversity of Cologne (Cologne,
Germany).
Study procedure. Each subject received the DA D2-class receptor an-
tagonist amisulpride (400 mg), the glutamate NMDA receptor antago-
nist memantine (20mg), or placebo in a double-blind cross-over design.
Sessions were separated by2 weeks to ensure complete washout of the
drug before the next session. The order of treatments was balanced across
subjects. Volunteers were informed about the drugs’ pharmacological
properties, their general clinical use, and possible adverse effects before
inclusion in the study. Exclusion criteria included history of neurological
or psychiatric illness, history of drug abuse, anduse of psychoactive drugs
ormedication in the 2 weeks before the experiment. In addition, subjects
were instructed to abstain from alcohol and any other drugs of abuse
during the entire course of the study.
After arrival, subjects first completed a visual analog scale (Bond and
Lader, 1974) to assess subjective effects of the drugs, such as sedation.
Thereafter, measurements of heart rate and blood pressure were ob-
tained. This was followed by administration of a pill that contained either
drug or placebo. fMRI measurements began 240 min after administra-
tion of drug or placebo, which is approximately the time at which those
drugs reach peak blood levels. Fifteen minutes before the start of fMRI
measurements (immediately before positioning in the scanner), subjects’
heart rate and blood pressure were again controlled and they received a
few practice trials on the learning task. In the scanner, subjects first
completed the reinforcement learning task, which lasted slightly 40
min. Thereafter, field maps were acquired for later B0 unwarping of the
functional images. This was followed by a 60-trial forced-choice
reaction-time task (still in the scanner, but without MRI measurements)
to control for possible drug-induced psychomotor slowing. Thereafter,
participants left the scanner room and completed the Trail Making Test
Part B. This was done to assess nonspecific drug effects on attention.
Then they filled out the visual analog scales a second time. Finally, sub-
jects’ heart rate and blood pressure were again measured and, if they felt
well, subjects were paid and released. After the final session, participants
were debriefed about the purpose of the study and about the order in
which they had received drug or placebo, respectively. We analyzed drug
effects on heart rate and on systolic and diastolic blood pressures by
separate two-way repeated-measures ANOVA with the factors DRUG
(three levels) and TIME (two levels; we only considered the baseline
measurement and the measurement immediately before fMRI). Drug
effects on subjective mood (measured by visual analog scales) were like-
wise tested by subjecting the visual analog scales to two-way repeated-
measures ANOVA with the factors DRUG (three levels) and ITEM (16
scale items).
Reinforcement learning task. We used an instrumental approach and
avoidance learning task similar to that used by Pessiglione and colleagues
(Fig. 1; Pessiglione et al., 2008; Fischer and Ullsperger, 2013). Each trial
started with presentation of a central fixation cross for a mean duration
of 1150 ms (jittered between 400, 900, 1400, and 1900 ms). Next, an
abstract symbol was presented centrally. One second after symbol onset,
participants were shown a response prompt that consisted of a check sign
and anX to the left and right of the option, respectively (side of check sign
and X balanced across participants). By pressing a left or right button,
subjects could indicate whether they wanted to select (check sign) or
reject (X) the option shown to them. There was a response window of
1.5 s within which subjects were required to respond. Each option had
a fixed probability p of yielding a monetary reward when chosen and a
fixed probability 1 p of yielding a monetary loss when chosen. Once a
response was made, the selected action (check sign for choose, X for
avoid) was highlighted by a rectangular frame until the outcome was
presented. Outcomes were revealed after a mean delay of 3.25 s (jittered
between 2.5, 3.0, 3.5, and 4.0 s) and consisted of a smiling face for re-
warded trials and a frowning face for punished trials. Outcomes were
shown for 700 ms. If no choice was registered within the required re-
sponse window, the words “please respond faster” appeared on the
screen, followed directly by the intertrial interval. Thus, no outcomes
were displayed on miss trials and hence no learning was possible follow-
ing a missed response. Importantly, on trials where participants decided
to avoid the option presented to them, they were nevertheless shown the
outcome that would have happened if they had chosen the option, but
this feedback was crossed out and shown in darker gray, indicating to
them that this had no financial consequences for them. This manipula-
tion allowed subjects to update their value estimates on each trial, regard-
less of their propensity to choose or avoid an option. For each rewarded
approach response, participants earned €0.1; for each punished ap-
proach response, €0.1was deducted.Outcomepresentationwas followed
by an intertrial interval of 0.4–3.4 s, during which a black blank screen
was presented. Participants completed three blocks of 90 trials each. In
addition, 30 null events (black screen for 6 s) were randomly interspersed
with the regular trials, resulting in a total experiment duration of 40
min. In each block of 90 trials, there were three different symbols that
were each shown 30 times. Depending on their associated probabilities to
yield reward or punishment when chosen, they were designated as
“good” (reward 0.7, punishment 0.3), “neutral” (0.5/0.5), or “bad”
(0.3/0.7) options. Thus, subjects’ goal was to learn to approach (select)
the good options in each block and to avoid (reject) the bad option. For
the neutral option, the ideal choice policy was to either always approach
it or always avoid it. Subjects were not explicitly informed that there was
always one good, one bad, and one neutral option. They were only told
that across the entire experiment, there were options that lead to losses
and some that lead to wins in the longer term. We calculated learning
curves separately for the three options by averaging subjects’ choices
(avoid 0, select 1) over the three blocks. Post hoc, we observed that
drug effects on learning became only apparent toward the end of each
block when performance reached an asymptote. We therefore used the
Bai–Perron multiple break point test (Bai and Perron, 1998) to identify
the number and location of structural breaks in the learning curves. The
test was implemented using the Matlab code provided online by the
authors. Using a minimum window of k trials (here, we set k to five
trials), the test can detect whether one or more breaks in the curve exist
and, if so, and howmany there are, based on the regression slope of each
possible segment and the resulting model fits. The test may find any
number of breaks between 0 and n/k  1 trials, where n equals the
number of trials. Thus, in our case, the test could reveal that between 0
and 5 breaks exist. The procedure was run using data from all subjects
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and all sessions, separately for the good and bad symbols. For both good
and bad symbols, the test detected two breaks that cut the learning curves
into three segments (see Results). We then calculated an index of final
learning performance by averaging the choice probabilities over the last
segment of the learning curve. This index was then subjected to two-way
repeated-measures ANOVA with the factors DRUG (three levels) and
VALENCE (two levels). Paired t tests were used as post hoc tests.
Forced-choice reaction-time task. This task was administered to test
whether the drugs caused a general response slowing. A fixation cross was
presented centrally. On each of the 60 trials, a symbolic square button
was presented horizontally to the left or right (30 left, 30 right in random-
ized order) of the fixation cross. Trials were separated by 1500 ms be-
tween the response and the onset of next stimulus. Subjects were
instructed to respond with the corresponding index finger as fast and as
accurately as they could. Subjects’ response times and number of correct
responses were compared between drug treatments using one-way
repeated-measures ANOVA with the factor DRUG (three levels).
TrailMaking Test Part B.TrailMakingTest Part B, a pencil–paper task,
requires subjects to connect letters and numbers in ascending order,
alternating between letters and numbers. This served as a test for atten-
tion and visuomotor speed. Time required for completion of the task was
compared between drug treatments using one-way repeated-measures
ANOVA with the factor DRUG (three levels).
Reinforcement learningmodel.Toobtain trial-by-trial estimates of sub-
jects’ reward expectation and PEs, we fitted a simple Rescorla–Wagner
model (Sutton and Barto, 1998; Jocham et al., 2011) to participants’
sequence of choices (approach or avoid) in the learning task. For each of
the three options in each block, the model learns a value by performing
the following update on each trial: V(k)t  1 V(k)t (k)t, where V
is the estimated value of option k on trial t, t is the PE on trial t, and  is
the learning rate that determines the degree to which  is used to update
option values. t Is the difference between rt, the reward obtained in trial
t, and V(k)t, the reward expected from option k on trial t: (k)t  rt 
V(k)t.
The model’s probability of selecting option k on trial t is then given by
a softmax choice rule as follows:
1
1  exp Vk	t/	
where the softmax temperature  is another free parameter that reflects
the degree of stochasticity in subjects’ choices. We used a Bayesian esti-
mation procedure custom-implemented in Matlab [MathWorks, Re-
search Resource Identifier (RRID):nlx_153890] routines to obtain the
free model parameters  and  that best describe subjects’ behavior. The
parameter space was set up as a two-dimensional grid in log space with
500 points in each dimension. The joint posterior distribution of the
unknownmodel parameters is then given by the product of choice prob-
abilities over trials under each possible parameter combination in the
grid. The marginal posterior distributions on each parameter were then
obtained by marginalizing (direct numerical integration) over the re-
maining dimension of the grid. The optimal parameters were then given
by the means of the resulting marginal posterior distributions.
Relative value learning model. When regressing the model-derived PE
against our fMRI data, we made an intriguing observation. PEs showed
the usual positive correlation with the BOLD signal on approach trials
(when subjects selected the option presented to them), but correlated
negatively on avoid trials (when subjects rejected the option; see Fig. 3).
By definition (t rt Vt) the PE consists of separable contributions of
the outcome term (higher rewards result in higher PE) and the expecta-
tion term (a higher expectation leads to lower PE). When decomposing
the PE into the outcome and expectation terms, we found that both
regressors had reverse effects on the BOLD signal on approach versus
avoid trials: there was a positive correlation of the fMRI signal with the
outcome on approach trials, but a negative correlation on avoid trials.
Likewise, there was a negative correlation with expected value on ap-
proach trials, but a positive correlation on avoid trials. This is unexpected
from standard reinforcement learning models. A learner that learns the
value of the stimuli would always experience a positive PE on rewarded
trials and a negative PE on punished trials, regardless of the action taken.
A model that learns state–action value pairs like SARSA (state–action–
reward–state–action) would behave the sameway on approach trials, but
generate no PE at all on avoid trials: subjects are clearly instructed that
avoiding the option always results in an outcome of zero, so the expected
value of option k given action A avoid is always zero. If the outcome is
set to be the really experienced outcome (zero), the PE is thus always zero;
if the outcome is set to be the outcome that would have happened, the
resulting PE would again be the same as in standard value learning (pos-
Figure 1. Top, Task schematic. Bottom, Learning curves for the rewarding (left), punishing (middle), and neutral (right) options under the three drug-treatment conditions. Values aremean
SEM. Statistics were computed on the averaged scores over the final segment of the block (bar graph insets, group means SEM). PLA, Placebo; AMI, amisulpride; MEM, memantine.
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itive on rewarded trials, negative on punished trials). However, an alter-
native possibility is that subjects learn a relative action value, that is, how
good action A is in comparison to the corresponding alternative action.
For example, a reward following an approach response indicates to the
subject that it has indeed been better to select this option rather than to
avoid it. The same rewarding outcome following an avoid response, how-
ever, indicates to the subject that it would have been better to take the
alternative approach action instead.We therefore use a simple modifica-
tion of the abovemodel, in which a relative valueRV is learned byRV(k)t
 1 RV(k)t (k)t.
Here, the PE  is computed as follows: (k)t rot RV(k)twhere ro is
the relative outcome, that is, the difference between the outcome ob-
tained under the action taken by the subject and the outcome that would
have happened under the alternative course of action, ochosen ounchosen.
Thus, ro simply corresponds to the experienced outcome on approach
trials (ro ochosen 0), but is the inverse on avoid trials [ro 0 1 for
rewarded trials and ro 0 (1) 1 for punished trials]. The net effect
of this algorithm in the context of our experiment is therefore simply that
the PE flips sign on avoid trials, which allows us to analyze approach and
avoid trials together.
MRI data acquisition.MRI data were acquired on a 3T Siemens Mag-
netom Trio equipped with a standard birdcage head coil. We acquired
1170 volumes per subject, with 30 slices (voxel size, 3 mm isotropic;
interslice gap, 0.3 mm) obtained parallel to the anterior commissure–
posterior commissure line using a single-shot gradient echo-planar im-
aging (EPI) sequence [TR, 2000 ms; TE, 30 ms; bandwidth, 116 kHz; flip
angle, 90°; 64
 64 pixel matrix; field of view (FOV), 192 mm] sensitive
to BOLD contrast. A high-resolution brain image (three-dimensional
reference dataset) was recorded from each participant in a separate ses-
sion using a modified driven equilibrium Fourier transform sequence.
For B0 unwarping of the EPI images, field maps were acquired using a
gradient echo sequence (TR, 1260 ms; TE, 5.20, 9.39, and 15.38 ms; flip
angle, 60°; 128
 128 pixel matrix; FOV, 210 mm) of the same geometry
as the EPI images.
MRI data analysis. Analysis of fMRI data was performed using tools
from the Functional Magnetic Resonance Imaging of the Brain Software
Library (Smith et al., 2004; RRID:birnlex_2067). Functional data were
motion-corrected using rigid-body registration to the central volume
(Jenkinson et al., 2002), corrected for geometric distortions using the
field maps and an n-dimensional phase-unwrapping algorithm (Jenkin-
son, 2003), high-pass filtered using a Gaussian-weighted lines 0.01 Hz
filter and spatial smoothing was applied using a Gaussian filter with 6
mm full-width at half-maximum. Slice time acquisition differences were
corrected using Hanning windowed sinc interpolation. EPI images were
registered with the high-resolution brain images and normalized into
standard (MNI) space using affine registration (Jenkinson and Smith,
2001). A general linear model (GLM) was fitted into prewhitened data
space to account for local autocorrelations (Woolrich et al., 2001). We
constructed two separate GLMs, one designed to investigate correlates of
PEs at the whole-brain level, the other to search for outcome-related
activity. Note that all of our analyses focus on region-of-interest (ROI)
analyses in the striatum. The results of GLM1merely serve to display the
whole-brain pattern of PE-related activity across all subjects, regardless
of treatment condition. GLM2provides the basis for defining orthogonal
ROIs for subsequent analyses of drug-induced differences in the stria-
tum. We focus our analyses on the striatum as the key region implicated
in reinforcement learning under the control of reward PEs. GLM1 con-
tained two regressors of interest: the relative value (modeled at stimulus
onset), derived from the relative value learning model, and the relative
outcome (modeled at outcome onset). These two regressors were entered
into the design matrix along with regressors modeling the main effect of
stimulus presentation, outcome presentation, and responses made by
subjects. In addition, the sixmotion parameters from themotion correc-
tion were included in the model. Contrasts were calculated for the ex-
pected value (1, because we expected negative correlations with
expected value), relative outcome, and the contrast for PE was set up by
contrasting the relative outcome regressor with the relative value regres-
sor. GLM2 was identical to GLM1 except that the regressors coding for
relative value and relative outcome were replaced by regressors coding
for the actual outcomes on each trial and the foregone outcomes, respec-
tively. The contrast for obtained outcomes was computed for this GLM.
Contrast images from the first level were then taken to the group level
using a random-effects analysis. Results are reported at a threshold of p
0.001, uncorrected.
ROI analyses. To obtain independent ROIs that are not subject to any
selection bias, we used the contrast of outcome-related activity from
GLM2 (see above) across all subjects in all three treatment conditions.
This yielded robust activations throughout the brain, particularly pro-
nounced in the striatum (peak MNI coordinates: x  17, y  7, z 
13, Z-max  7.28, and x  15, y  9, z  13, Z-max  7.27). The
contrast image was thresholded at z 3.9 and multiplied with anatom-
ical masks, first for the entire striatum, and subsequently separately for
the caudate nucleus, putamen, and ventral striatum from the Harvard–
Oxford subcortical atlas. We merged the resulting masks for the two
hemispheres, thus resulting in one ROI each for caudate, putamen, ven-
tral striatum, and entire striatum. We extracted raw BOLD signal time
courses from the above ROI. Using custom-written Matlab (RRID:
nlx_153890) code, the following steps were then performed. The time
series of each volunteer was cut into trials with a duration of 14.31 s,
where options were presented at 0 s, the response wasmade at 1.42 s, and
the outcome was presented at 4.31 s, which corresponds to the mean
onsets of these events across subjects, trials, and sessions. Time series
were resampled to a resolution of 200ms. A GLM containing the param-
eters of interest was then fitted at each time point for each volunteer. This
resulted in a time course of effect sizes for each regressor in the design
matrix and for each volunteer. These time courses were then averaged
across participants. The GLM was set up to decompose the PE into its
constituent terms, expectation and outcome. For a signal to truly repre-
sent a PE, it has to comply with two key formal criteria: (1) it has to be
sensitive to variations in both expectation and outcome, and (2) the
effect of outcome on the BOLD signal has to be positive because, for any
given expectation, a larger reward will generate a larger PE. In contrast,
for any given outcome, a higher expectation decreases the PE; hence the
effect of expectation on the BOLD signal (at the time of outcome) has to
be negative (Caplin and Dean, 2008; Rutledge et al., 2010). The design
matrix therefore contained the relative values and relative outcomes,
with separate regressors for appetitive and aversive trials. Appetitive and
aversive here refers to the outcome available for the symbol on each trial,
e.g., trials on which a reward is observed (experienced or foregone) are
considered “appetitive,” whereas trials where a punishment is observed
are considered “aversive.” This classification is due to our hypothesis that
amisulpride would be involved in both approach and avoidance learning
by reporting both the increase and decrease in DA levels during positive
and negative PEs, respectively, whereas we expectedmemantine to inter-
fere selectively with approach learning by preventing the phasic increases
in DA levels during positive PEs. For statistical testing, the time course of
effect sizes was summed in the time window from 4–8 s after outcome
presentation, which is where the peak effects are expected to occur. These
values were then entered into a two-way repeated-measures ANOVA
with the factors DRUG (three levels) and VALENCE (two levels). Paired
t tests were used as post hoc tests.
Results
Behavior
We excluded two participants because of an extreme number of
misses (40) in 1 of the three sessions, which prevented reli-
able computation of learning curves. Response misses were rare
among the remaining volunteers (median, 1, 2, and 2 misses for
the placebo, amisulpride, and memantine conditions) and did
not differ between drug conditions (p 0.08). All further anal-
yses were therefore performed on this final sample of n  22
subjects.
Participants quickly learned to select rewarding options and
to avoid punishing stimuli (Fig. 1). In contrast, for neutral op-
tions, the percentage of subjects selecting this option remained at
50% throughout the course of learning. When considering the
entire course of learning, no clear differences in approach learn-
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ing between treatment conditions became evident. However, it
appeared that learning curves diverged late in the blocks when
learning had stabilized, with the plateau reached at the end of the
block seeming to be higher under placebo than under either me-
mantine or amisulpride. To find systematic breaks in the learning
curves that allowed us to divide learning into early and final
stages, we applied the Bai–Perron multiple break point test (see
Materials and Methods). The test was applied to learning data
across participants. Two breaks were identified for both ap-
proach and avoidance learning that split the learning curves into
three stages. For approach learning, these breaks were detected at
trials 10 and 19; for avoidance learning, breaks were detected at
trials 6 and 15. In the final segment, approach learning was im-
paired by both amisulpride and memantine. In contrast, avoid-
ance learning was impaired only by amisulpride, but not by
memantine (Fig. 1). Two-way ANOVA on the averaged score
during the final segment revealed an effect of VALENCE (F(1,21)
 18.78, p  0.0001), no effect of DRUG (F(1,21)  2.237, p 
0.119), but amarginally significant DRUG
VALENCE interac-
tion (F(2,42)  2.92, p  0.065), indicating that drugs affected
learning and did so differently for approach versus avoidance
learning. Post hoc t tests showed that final learning performance
was reduced under amisulpride compared with placebo (t(21) 
2.1, p  0.024) and under memantine compared with placebo,
although this effect fell just short of statistical significance (t(21)
1.63, p  0.059). In contrast to approach learning, avoidance
learning was impaired only by amisulpride (t(21)  2.65, p 
0.0075), but not bymemantine (t(21) 0.49, p 0.3). The effects
of amisulpride on avoidance learning appeared more pro-
nounced than those on approach learning because a significant
learning impairment compared with placebo became evident
evenwhen considering the summed score over the entire learning
curve (t(21) 2.56, p 0.009).
The behavioral effects of these drugs occurred in the absence
of any effects on response speed,measures of attention, subjective
mood, heart rate, and blood pressure. Neither response time nor
the number of incorrect responses on the forced-choice reaction-
time task showed an effect of DRUG (p  0.44). Likewise, time
taken to complete the Trail Making Test Part B, a measure of
visual attention, was not influenced by DRUG (p  0.36), nor
was there an effect of DRUG on subjective mood rating (p 
0.89). Finally, neither heart rate nor systolic or diastolic blood
pressure was influenced by DRUG (p 0.37).
Neither the learning rates [  0.0175  0.0042, 0.0266 
0.0067, and 0.0221 0.0061 (mean SEM) for placebo, amisul-
pride, and memantine, respectively] nor the temperatures ( 
0.0533  0.0194, 0.1328  0.0446, and 0.1131  0.0432) esti-
mated for the reinforcement learning model differed as a func-
tion of DRUG (p  0.26). However, there was a trend for an
effect of DRUG on the model fits (negative log likelihoods, p 
0.094).Whenwe followed this up by post hoc t tests, we found that
the model fit was worse under amisulpride compared with pla-
cebo (p  0.0052), but not under memantine (p  0.5) com-
pared with placebo [negative log likelihoods: 126.23  5.73,
140.41  6.5, and 130.58  6.6 (mean  SEM), for placebo,
amisulpride, and memantine, respectively]. The model’s proba-
bility for generating the choices made by participants was signif-
icantly above chance for good [0.75  0.015 (mean  SEM)
model choice probability], bad (0.75 0.017), and neutral sym-
bols (0.52 0.0037, all t(65) 43, p 10 * 10
37). Themodel was
able to accurately reproduce subjects’ choice behavior (Fig. 2).
Again, two-way ANOVA on the averaged score during the final
segment revealed an effect of VALENCE (F(1,21)  403.58, p 
0.0001), no effect of DRUG (F(1,21)  0.252, p  0.778), but a
marginally significant DRUG
VALENCE interaction (F(2,42)
3.19, p 0.051). Likewise, post hoc t tests showed that the mod-
eled final learning performance was reduced under amisulpride
compared with placebo (t(21)  3.17, p  0.0023) and under
memantine compared with placebo, although this effect fell just
short of statistical significance (t(21)  1.66, p  0.056). In con-
trast, the model’s avoidance learning was impaired only by
amisulpride (t(21)  3.16, p  0.0024), but not by memantine
(t(21) 1.53, p 0.07).
BOLD correlates of reward PEs
When we first performed our fMRI analyses using a simple stim-
ulus value learning method, we made the intriguing observation
that the correlation of the fMRI signal with the model-derived
PEs flipped signs between approach and avoid trials (see Materi-
als and Methods). We show this in Figure 3 using data from our
ROI in the putamen, but the same results are obtained when
using the other two striatal ROIs. This figure shows the PEs across
all subjects in all three drug treatments, split up into trials where
the subjects selected the option or where they avoided it (Fig. 3,
left). The positive PE correlate is a result of both a negative cor-
relation with the expected value and a positive correlation with
the outcome. When decomposing the PEs into these constituent
terms, we find that both effects flip signs. On approach trials, the
usual pattern is observed (positive correlation with outcome and
negative correlation with expected value; Fig. 3, middle). On
Figure 2. Learning curves derived from the reinforcement learning model. Model choice probabilities to select the option presented to it were computed using the learning rate and softmax
temperature fitted for each subject and the sequence of options presented and outcomes observed by the model. Values are mean SEM.
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avoid trials, however, both effects reverse in the opposite direc-
tion (Fig. 3, right). Thismight be suggestive of a PE that is used to
update the relative, rather than absolute value of actions. We
implemented a relative value learning algorithm that learns rela-
tive values simply by substituting the relative outcome (outcome
of the chosen actionminus outcome of the alternative action) for
the experienced reward. This has interesting implications for
studies with two (or more) separate options with uncorrelated
outcomes and new choice contexts. For the purpose of our cur-
rent study, this procedure simply serves to bring PEs from ap-
proach and avoid trials into the same reference frame so they can
be analyzed together. The resulting model choice probabilities of
the two algorithms are (by design) identical. Our following re-
sults therefore report the effects of relative value PEs, or their
component terms, relative values, and relative outcomes.
Whole-brain correlates of relative value PEs
We found activity covering ventral parts of the striatum (ventral
caudate, ventral putamen and ventral striatum, peaks atMNI x
14, y 7, z4, Z-max 4.77, and x 15, y 15, z3,
Z-max  4.7) and in the anterior midcingulate cortex (aMCC;
MNI: x7, y 20, z 43, Z-max 5.47, and x 12, y 27,
z 39, Z-max 5.2) to correlate with the relative value PE (Fig.
4, left).When looking at the component terms (relative value and
relative outcome), we found both a strong negative effect of rel-
ative value (MNI: x14, y 7, z4, Z-max4.65, and
x  15, y  15, z  3, Z-max  4.5) and a strong positive
effect of relative outcome (MNI: x  19, y  9, z  11,
Z-max 8.84, and x 20, y 9, z10, Z-max 8.6) in the
striatum (Fig. 4, middle, right). Interestingly, in the aMCC we
only found a strong negative effect of relative value (MNI: x 
Figure 3. Time course over the course of a trial of the correlation of the BOLD signal from an ROI in the putamenwith the PE derived from a standard Rescorla–Wagnermodel. Left, PE correlates
positively with putaminal BOLD signal on approach trials. On avoid trials, however, the effect reverses to a negative correlation between PE and BOLD signal. When further decomposing the PE into
its component terms, expected value and outcome, separately for approach (middle) and avoid (right) trials, it shows that both the effects of outcome and expectation reverse signs on the avoid
trials. Values represent regression coefficients obtained frommultiple linear regression; solid lines are means of all subjects collapsed across the three conditions. Shaded areas represent the SEM.
Figure4. Whole-brain effects of the relative valuePEat outcome time. Left, Effect of the contrast relative valuePE (relative outcomeminus relative value).Middle, Right, Effects of the component
terms relative value (middle) and relative outcome (right) show that the positive effect of relative value PE in the striatum (left) is a result of both a negative effect of relative value and a pronounced
positive effect of relative outcome (right). In the aMCC, the relative value PE effect seems to arise primarily from a negative effect of relative value, without a clear positive effect of relative outcome
in the same region. Note, however, the strong positive relative outcome effects in adjacent mesial cortical areas. Images are thresholded at Z 3.1.
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7, y 20, z 43, Z-max5.47, and x 12, y 27, z 39,
Z-max5.2), but no positive effect of relative outcome.
Pharmacological effects on striatal PE coding
Using the procedure above, we were able to obtain data from
three ROIs that are not subject to any selection bias. Those ROIs
lie in the caudate, putamen, and ventral striatum. In addition, an
overall striatal ROI was created by merging the three subterrito-
ries. We divided PEs up into appetitive and aversive trials, be-
cause the availability of a reward (appetitive trial), experienced or
observed, will promote approach behavior, whereas the availabil-
ity of a punishment (aversive trial), experienced or observed, will
promote avoidance behavior. We find that both amisulpride and
memantine diminished appetitive PEs. In contrast, aversive PEs
were only reduced under amisulpride, while memantine had no
effect. Two-way ANOVA on the whole-striatal PEs yielded
an effect of DRUG (F(2,42)  3.8, p  0.03), but no effect of
VALENCE (F(1,21) 0.016, p 09), and noVALENCE
DRUG
interaction (F(2,42) 1.96, p 0.15). Again, post hoc tests showed
that amisulpride diminished both the appetitive (t(21) 2.23, p
0.018) and aversive PEs (t(21)  1.852, p  0.039). In contrast,
memantine only reduced the appetitive PEs (t(21)  2.38, p 
0.014), but had no influence on the aversive PEs (t(21) 0.44, p
0.33; Fig. 5). To investigate this effect in more detail, we used a
design matrix (see Materials and Methods) that decomposed the
PE into its component terms, relative value, and relative out-
come, separately for approach and avoid trials and applied this
analysis separately to each of the three striatal subterritories. We
find the expected negative effect of relative value following pre-
sentation of the outcome. However, this representation was not
affected by either of the drugs. Two-way ANOVA revealed nei-
ther an effect of DRUG nor a DRUG
VALENCE interaction in
any of the three striatal ROIs (Fig. 6; all p  0.2). In contrast to
this, for relative outcome (Fig. 7), two-way ANOVA in the cau-
date yielded an effect of DRUG (F(2,42)  4.34, p  0.0194),
VALENCE (F(1,21)  11.92, p  0.0031), but no VALENCE 

DRUG interaction (F(2,42)  1.04, p  0.36). Post hoc tests
showed that under amisulpride, both the appetitive (t(21) 2.32,
p 0.015) and aversive (t(21) 2.02, p 0.0277) outcome signal
was reduced comparedwith placebo.Undermemantine, only the
relative outcome signal on appetitive trials (t(21)  2.2, p 
0.0195), but not on aversive trials (p  0.46), was attenuated
compared with placebo. In the putamen, two-way ANOVA
yielded an effect of DRUG (F(2,42)  3.586, p  0.0365), but
no effect of VALENCE (F(1,21)  2.138, p  0.1585), and no
VALENCE
DRUG interaction (F(2,42) 1.608, p 0.2123). As
in the caudate, post hoc tests again showed that under amisul-
pride, the relative outcome effect in both appetitive (t(21) 1.99,
p  0.03) and aversive trials (t(21)  1.87, p  0.0375) was re-
duced compared with placebo. Likewise, under memantine,
again only the appetitive (t(21)  2.14, p  0.022) but not the
aversive (p 0.4) outcome signal was attenuated compared with
placebo. In the ventral striatum, two-way ANOVA yielded a
trend for an effect of DRUG (F(2,42) 2.825, p 0.07), an effect
of VALENCE (F(1,21)  5.489, p  0.0291), and a trend for a
VALENCE
 DRUG interaction (F(2,42) 2.73, p 0.077). De-
spite the effect of drug being only present as a trend, we followed
this up with our preplanned comparisons because of our strong a
priori hypothesis. We found that both amisulpride (t(21) 3.17,
p 0.0023) and memantine (t(21) 2.7, p 0.0067) treatment
decreased the outcome signal on appetitive trials, thus mirroring
the pattern in the other two striatal ROIs. In contrast to this, the
outcome signal on aversive trials in the ventral striatum remained
unaffected by either drug (both p 0.16). Together, by showing
that the striatal signal shows both the positive correlation with
relative outcome and the negative correlation with relative value
at the time of outcome, we demonstrate that the striatal signal
fulfils the required formal criteria for a PE signal. We further
demonstrated that both drugs modulated the effects of the (rela-
tive) outcome term and did not affect representations of expected
(relative) value. Finally, to test whether the drugs differentially
affected relative outcome representations in the three striatal re-
gions, we performed a three-way ANOVA with the factors ROI
(caudate, putamen, ventral striatum), DRUG (placebo, amisul-
Figure5. Drug effects on striatal PE representations. Here, the striatal ROIs (caudate, putamen, and ventral striatum)weremerged into one conglomerate striatal ROI. Time courses represent the
correlation of the effect size differences of relative outcome minus relative value on the BOLD signal from this ROI. Amisulpride diminished both appetitive (left) and aversive (right) PEs, while
memantine only attenuated appetitive, but not aversive PEs. Values represent regression coefficients obtained frommultiple linear regression; solid lines are groupmeans for each drug condition.
Shaded areas represent the SEM. PLA, Placebo; AMI, amisulpride; MEM, memantine.
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pride, memantine), and VALENCE (appetitive, aversive). We
found main effects of DRUG (F(2,42)  3.97, p  0.026),
VALENCE (F(1,21)  7.647, p  0.012), and ROI (F(2,42) 
16.131, p 0.001), but no DRUG
 ROI nor a DRUG
 ROI

VALENCE interaction (p  0.45), suggesting that drug effects
did not differ between the three ROIs. When looking at the pat-
tern of the effects (Fig. 7, bottom right), we note that the aversive
outcome correlate in the ventral striatum seems to have temporal
characteristics that slightly deviate from the other signals. In par-
ticular, we observe an initial negative dip following the outcome,
followed by a later positive peak. We do not know the reason for
this, but we observe that under placebo, the negative dip seems
slightly more pronounced than under drug. Thus, it might be
possible that when considering the amplitude of this effect from
base to peak, there may still be a significant difference between
conditions.
Discussion
In this study we combined fMRI with pharmacological antago-
nismofD2 andNMDAreceptors to test their differential involve-
ment in approach and avoidance learning and in the expression
of appetitive and aversive PEs. We found that D2 antagonism
with amisulpride impaired both approach and avoidance learn-
ing concomitant with blunting of both appetitive and aversive PE
signals in subregions of the striatum. In contrast, memantine
mildly attenuated approach learning without affecting avoidance
learning, which was paralleled by a reduction of appetitive, but
not aversive PE signals in striatal subregions.
Figure6. Time course over the course of a trial of the correlation of relative value (RVAL)with the BOLD signal in three independently defined striatal ROIs in the caudate (top), putamen (middle),
and ventral striatum (bottom), separately for appetive and aversive trials (trials in which reward or punishment, respectively, were available, regardless of whether or not this outcome had been
experiencedoronlyobserved). Values represent regression coefficients obtained frommultiple linear regression; solid lines aregroupmeans for eachdrug condition. Shadedareas represent theSEM.
PLA, Placebo; AMI, amisulpride; MEM, memantine.
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There are 3 candidate mechanisms that could explain the
attenuation of appetitive learning after NMDA receptor antago-
nism. Our working hypothesis was built on the evidence that
phasic activation of midbrain DA neurons is driven by glutama-
tergic afferents acting via NMDA receptors localized on DA neu-
rons in the midbrain (Overton and Clark, 1992; Wang et al.,
2011). However, DA release in the striatum is also enhanced by
local NMDA receptors, possibly localized directly on the dopa-
minergic terminals (Krebs et al., 1991; Ohta et al., 1994; Iravani
and Kruk, 1996; Che´ramy et al., 1998). This mechanism could
also account for the diminished appetitive PEs we observed in the
striatum. In addition, direct infusion of NMDA receptor antag-
onists into the ventral striatum impairs appetitive instrumental
learning (Kelley et al., 1997). This effect might operate at the
postsynaptic level, independently of modulation of DA release.
The effects of NMDA receptors and DA converge on the same
signaling pathways (Konradi et al., 1996) and combined admin-
istration of NMDA and DAD1 receptor antagonists at doses that
are ineffective when given alone impair appetitive instrumental
conditioning (Smith-Roe and Kelley, 2000). Finally, it has to be
noted that NMDA receptors are widely expressed throughout the
brain, in particular in neocortex. Thus, given that we used sys-
temic drug administration, an action at extrastriatal sites cannot
be ruled out.
In contrast to NMDA receptors, D2 receptors are required for
detecting both phasic increases anddecreases in striatalDA levels.
Our finding that amisulpride interfered with both approach and
avoidance learning is in agreement with rodent studies showing
impairments in appetitively and aversivelymotivated instrumen-
tal learning following blockade of striatal D2 receptors (Salam-
one, 2002; Wise, 2004; Salamone et al., 2005). The evidence in
humans is more mixed (for review, see Ullsperger et al., 2014).
Figure 7. Same as in Figure 6, but here the effect of relative outcome is shown (obtained from the same GLM as the relative value effects in Fig. 6). PLA, Placebo; AMI, amisulpride; MEM,
memantine. The representation of outcomes was attenuated by both amisulpride and memantine on appetitive trials, but only by amisulpride on aversive trials.
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Studies using the paradigm developed by Frank and colleagues
(Frank et al., 2004) found that Parkinson’s patients (who suffer
from DA depletion in the dorsal striatum) are biased to better
learning from negative outcomes, which is reversed under treat-
mentwith L-DOPA (Frank et al., 2004, 2007).Using the same task
in healthy volunteers, the D2 receptor antagonists haloperidol or
amisulpride (Frank and O’Reilly, 2006; Jocham et al., 2011) bi-
ased learning toward better learning from positive outcomes,
whereas the reverse bias was found under the influence of the D2
agonist cabergoline (Frank and O’Reilly, 2006). These effects are
remarkably consistent with a mechanistic model of basal ganglia
DA function that relates approach and avoidance learning to dif-
ferential DA effects on synaptic plasticity in the direct and indi-
rect pathway of the striatum (Frank, 2005). It has to be borne in
mind, however, that the task used in these studies consists of an
initial learning stage and a later transfer phase that requires par-
ticipants to make choices on the basis of the previously learned
values. None of the above studies report any effects on the initial
learning. The effects are found when choices between novel pair-
ings are made, in the absence of any feedback. There is evidence
that DA effects in this task may, at least in part, be mediated by
affecting instrumental performance during the transfer phase,
rather than, or in addition to, an effect on learning (Jocham et al.,
2011; Shiner et al., 2012). In a task using an asymmetric reward
schedule, pramipexole reduced reward learning (Pizzagalli et al.,
2008). This task, however, did not capture effects on punishment
learning, and there was evidence for nonspecific effects (seda-
tion) of pramipexole. Using a subliminal instrumental learning
task, Palminteri and colleagues found that unmedicated
Tourette’s patients (likely suffering from a hyperdopaminergic
state) were better at appetitively motivated learning than at aver-
sivelymotivated learning. This bias was reversed under treatment
with neuroleptic drugs (risperidone, pimozide), agents that pri-
marily target D2 receptors. The reverse pattern was found in
Parkinson’s patients, who showed a bias to better punishment
learning in the nonmedicated state, which was reversed in the
medicated state (Palminteri et al., 2009). The same group also
found that haloperidol attenuated approach learning and appet-
itive striatal PEs relative to L-DOPA, without affecting avoidance
learning and aversive striatal PEs in healthy humans (Pessiglione
et al., 2006). We have previously found improved learning from
rewarding outcomes and enhanced striatal PE coding under a
lower dose of amisulpride (200 mg; Jocham et al., 2011). This
dose was chosen to primarily achieve a blockade of somatoden-
dritic autoreceptors, thereby possibly facilitating phasic DA neu-
ron firing and subsequent DA release during positive PEs. In
contrast, the dose in the current study (400 mg) was chosen on
the basis of studies showing that this dose is sufficient to achieve
occupation of 50–80% of postsynaptic striatal D2 receptors
(Martinot et al., 1996; Bressan et al., 2004; la Fouge`re et al., 2005;
Meisenzahl et al., 2008), thereby preventing the detection of ei-
ther increases or decreases in DA levels by striatal D2 receptors.
The drug effects on reinforcement learning we observed were
rather modest. One possible reason for this is that learning in our
task was not exclusively reliant on striatal mechanisms. It is pos-
sible that our subjects deployed additional, possibly more declar-
ative strategies to solve the task. Our task was similar to the
paradigm used by Pessiglione and colleagues (Pessiglione et al.,
2008; Palminteri et al., 2009). In their studies, due to the sublim-
inal presentation of stimuli, performance never reached the same
plateau as in our present findings. It is possible that such learning,
which possibly relies predominantly on the striatum, would have
been easier to perturb with pharmacological challenges. Regard-
ing the choice of our NMDA antagonist, there are drugs that are
more potent at blocking NMDA receptors, e.g., ketamine. It is
possible that NMDA receptor antagonism with ketamine would
have revealed more pronounced effects. However, due to the
general role of NMDA receptors in cognition (Robbins andMur-
phy, 2006), one might easily obtain diffuse cognitive impair-
ments under highly potent NMDA receptor antagonism. A third
possibility is that the high-amplitude PEs that occur early in the
course of learning are still able to override the pharmacological
effects (at least in the case of phasic DA activation), whereas the
smaller PEs during the final stages as learning stabilizes may
be more vulnerable to our drug challenge. Finally, an alternative
explanation of our findings is that drugs did not affect reinforce-
ment learning at all, but instead reflected effects on instrumental
performance. At least in the case of DA, there is clear evidence for
drugs also affecting instrumental performance (Jocham et al.,
2011; Shiner et al., 2012; Eisenegger et al., 2014). Future studies
might employ protocols that run either a learning phase in the
drugged state or a later probe trial phase in the drugged state
(with learning in the drug-free state). However, while we cannot
exclude a performance effect, we also note that the behavioral
effects are precisely mirrored by the drug effects on striatal rep-
resentations of reward PEs.
The fit of our reinforcement learning model to subjects’ be-
havior was poorer under amisulpride compared with placebo.
Onemight argue that our finding of reduced appetitive PE coding
in the striatum under amisulpride might be a reflection a less
accurate estimation of subjects’ PEs in this drug treatment.While
this is possible, we have decomposed the PEs into its component
terms, relative values, and relative outcomes. We find that the
drug effects on striatal PEs arise fromamodulation of the effect of
relative outcomes, not relative values. While relative value is a
parameter estimated by themodel, relative outcome is simply the
difference between the experienced outcome and the outcome
that would have resulted from the alternative course of action.
Therefore, our results are immune to differences in model fits
between drug treatments.
We made the entirely unpredicted observation that our PEs
derived from a standard Rescorla–Wagner model showed the
expected positive correlation with the striatal fMRI signal on ap-
proach trials, but reversed to a negative correlation on avoid
trials. This pattern is not expected from standard reinforcement
learning models and may provide a hint that this signal instead
codes a PE that is used to learning a relative value, that is, how
good an action is relative to its alternatives. We are currently
exploring this possibility further. Here, we can’t provide further
evidence in support of this idea because we do not have uncorre-
lated alternative outcomes. Other fMRI studies have already
found evidence for so-called fictive PEs (difference between re-
ward obtained and maximum possible reward) in the human
striatum (Lohrenz et al., 2007; Chiu et al., 2008). Taking advan-
tage of the millisecond resolution of EEG, Fischer and Ullsperger
(2013) used a task almost identical to the one used here and
showed that the spatiotemporal dynamics of real and fictive out-
come processing differed during the initial 400 ms after outcome
presentation, but then converged onto a common final pathway.
Our findings show that D2 receptor antagonism interfered
with both approach and avoidance learning, concomitant with
reduced expression of both appetitive and aversive PEs in the
striatum. NMDA receptor antagonism attenuated approach
learning and appetitive PE coding in the striatum, without affect-
ing avoidance learning and aversive PEs in the striatum.
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